In this work, we introduce a new customized anti-lung cancer peptide, CB1a, with IC 50 of about 25.0 ± 1.6 μM on NCI-H460 lung cancer cells. Using a multi-cellular tumor spheroid (MCTS) model, results show that CB1a is potent in preventing the growth of lung cancer tumor-like growths in vitro. Additionally, atomic force microscopy (AFM) was used to examine cell surface damage of a single cancer. The mechanism for cell death under CB1a toxicity was verified as being largely due to cell surface damage. Moreover, with a treatment dosage of CB1a at 25 μM, Young's module (E) shows that the elasticity and stiffness of cancer cell decreased with time such that the interaction time for a 50% reduction of E (IT 50 ) was about 7.0 min. This new single-cell toxicity investigation using IT 50 under AFM assay can be used to separately verify drug efficacy in support of the traditional IC 50 measurement in bulk solution. These results could be of special interest to researchers engaged in new drug development.
Introduction
As natural antibiotics, most antimicrobial peptides (AMPs) have both cationic and amphipathic properties that allow them to interact with bacterial cytoplasmic membranes leading to cell death [1] [2] [3] [4] . Mutation of these natural AMPs can significantly alter bacterial killing ability. For example, a recent study showed that N-acylated mutant of LF11 derived from human latoferricin could enhance antimicrobial activity on Escherichia coli [5] . Some AMPs such as cecropins [6] [7] [8] , magainins [9] [10] [11] [12] [13] [14] , melittins [15] [16] [17] , human LL-37 [18] [19] [20] [21] [22] [23] and host defense peptides [24, 25] have the ability to kill cancer cells. Both cell-killing mechanisms (antimicrobial and anticancer) may share similarities such as membranolysis [26] [27] [28] [29] [30] . Among these peptides, melittin is the most toxic to human cells. However, a recent report [31] showed that if melittin was used to form complexes with nanoparticles, its anti-cancer ability could be enhanced, half-life increased, and toxicity in mice decreased. These observations imply that under particular circumstances altering original peptides can make them more effective in killing cells [30] .
Cecropins (such as cecropins A, B, C, D, E and F) belong to a family of natural antimicrobial peptides composed of 34-39 amino acids of high sequence homology [7, 32] . These peptides have common characteristics. They are mostly constructed with α-helical structure at the amphipathic N-terminal (where one side is hydrophilic and the other hydrophobic) and the hydrophobic residues of the C-terminal. Cecropin B (CB) has the strongest antibacterial activity of this family. Our previous studies have shown that CB can disrupt bacterial membranes and also kill cancer cells including leukemia, stomach carcinoma, and lung cancer cells [33] [34] [35] [36] [37] [38] . However, the efficacies of CB on killing cancer cells were not as good as for killing bacteria as compared with other anti-cancer agents. The possible explanation is that CB which is naturally good to kill bacteria may not be good to apply it for killing such as cancer cells where the surface conformations are different from bacteria's. For the purpose of developing an effective anti-cancer peptide, therefore, a new design using natural CB's sequence as a template is essential. Accordingly, peptide, CB1a, was constructed by using three-repeated amphiphathic section of the CB N-terminal (Lys-Trp-Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys or KWKVFKKIEK) and bridged with Ala-Gly-Pro (or AGP) as: NH 2 -KWKVFKKIEK-KWKVFKKIEK-AGP-KWKVFKKIEK-COOH (see Ref. [39] for details). Nuclear Magnetic Resonance (NMR) structural study showed that CB1a has two helices kinked (kink angle: 110°) by a bridge, Ala-Gly-Pro (see RCSB-Protein Data Bank; 2IGR). The advantages in creating CB1a as a custom anticancer peptide were: (i) Proline involved in the bridge or kink section as it can be effectively used for oligomerization and pore gating in the lipid bilayer of cancer cell membranes [40, 41] ; (ii) The three repeated amphipathic sections of CB1a allow for high flexibility to dynamically pass through the cell surface to the cell lipid bilayer; (iii) The high density of positive charge (net +12) which provides strong binding capacity with cancer cell membranes, which have a high negative Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / b b a m e m charge due to lipids [30] . Consequently, the customized peptide CB1a met both the selectivity and toxicity criteria for killing cancer cells [39] . Since CB1a likely kills cancer cells in a similar way as the AMPs mentioned above i.e., through lipid corruption at the membrane, the method is described as a physical rather than chemical attack. Chemical attacks describe inhibition of chemical reactions at binding sites inside the cell such as those for RNA and DNA. To measure the physical changes in cancer-cell surfaces before and after physical attack by CB1a, both the elastic force and morphological changes of the cell membrane were analyzed by atomic force microscopy (AFM). Comparisons of stiffness between cancer and normal cells via AFM measurements have been previously reported and confirmed in terms of clinical concerns about the stiffness of cells, which varies according to the different mechanical characteristics of membranes [42] [43] [44] [45] [46] [47] [48] . Most recently, mechanical stiffness has been correlated with the plasma membrane potential of vascular endothelial cell using a combination of fluorescence-based membrane potential recording and AFM-based stiffness measurements [49] . Unlike electron microscopy, AFM does not require any additional cell-preparation treatments and samples can be imaged under nearly native conditions with minimal alteration or damage. Additionally, AFM allows for real-time observation of cell morphological changes.
In this study, we verify the efficacy of CB1a on lung cancer cells in bulk solution using half maximal inhibitory concentration (IC 50 ) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. A multi-cellular tumor spheroid (MCTS) model in test tubes is also applied to show that CB1a is potent in preventing the growth of lung cancer tumor-like growths. Furthermore, we identify the killing pathway for a single cancer cell by observing damage to the cell surface under AFM measurements. Results show that CB1a has high selectivity for cancer cells over normal lung cells. While, doxorubicin (Dox) currently used in clinics does not have high selectivity and causes damage to both normal lung and cancer cells, which can lead to serious side effects in patients. Since CB1a has both low toxicity and high selectivity, it may make a good candidate for further development as an anti-cancer drug.
Materials and methods

Materials
The AFM tip (pointprobe®) was purchased from Nanosensor (Switzerland). Micro-particle (diameter~10 μm) was obtained from Bangs Laboratories (USA). Cell culture media, fetal bovine serum (FBS) and antibiotics-penicillin and streptomycin were purchased from Gibco (USA). RPMI-1640 medium, hydrochloride acid, sodium bicarbonate and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were obtained from Sigma (USA). Doxorubicin was purchased from Pfizer (Italy). Cancer cell lines NCI-H460/NCI-H520 and fibroblast cell line MRC-5 were purchased from the American Type Culture Collection (ATCC; USA). Water used was de-ionized and distilled.
Preparation of peptides
Both CB1a and CB peptides were solid-phase synthesized by peptide synthesizer (Applied Biosystem Inc.) [50] . Fmoc (9-fluorenylmethyloxycarbonyl) and HBTU (O-benzotriazole-N,N,N′, N′-tetramethyl-uronium-hexafluoro-phosphate)/HOBT (N-hydroxybenzotriazole) were used as protection and coupling reagents, respectively. Final products were de-protected and cleaved from the peptide resin using a solution containing tri-fluoroacetic acid (TFA), water, phenol, thioanisole and ethanedithiol. The remaining resin was removed by filtration and the peptides precipitated with diethyl ether after the organic solvents had evaporated. The crude peptides were desalted on Sephadex G-10 (20% acetic acid) and purified by reverse phase high pressure liquid chromatography (HPLC) (Vydac C-18 column, 0.1% TFA in H 2 O-acetonitrile). Product purities were determined by HPLC and found to be 95% and 96% for CB1a and CB, respectively. Molecular weights (MWs) of the peptides were determined by mass spectrometry and found to be almost identical to the theoretical values (Both observed/calculated MWs (g/mol) are 4191.2/4190.3 and 3834.8/3836.0 for CB1a and CB, respectively). Concentrations of peptides were determined from the net weight of peptides and their molecular masses (the weight of associated counter ions was not taken into consideration).
Cell culture and cytotoxicity assays
Lung cancer cell lines (NCI-H460 and NCI-H520) were grown in RPMI-1640 culture media supplemented with 10% FBS and 1% penicillin-streptomycin (PS) antibiotic mixture. Lung fibroblast cell line (MRC-5) was cultured in MEM medium containing 10% FBS and 1% PS mixture. The above cell lines were cultured at 37°C in a 5% CO 2 humidified incubator.
The cell suspensions were adjusted to contain 1 × 10 5 cells/ml before they were transferred into a 96-well plate (90 μl/well). Fig. 1 .
Multi-cellular tumor spheroid culture
Multi-cellular tumor spheroids (MCTS) of NCI-H460 cancer cells were constructed on non-adhesive, bacterial culture-grade polystyrene Fig. 1 . IC 50 measurements of CB1a on lung cancer cell line, NCI-H520. Two measurements were done (CB1a peptides were produced by different batches, CB1a_1 and CB1a_2, respectively). IC 50 of CB1a was about 25.0±1.6 μM. Each point was the average of five experimental measurements.
Petri dishes using a modified hanging drop method [51] . Approximately, 500 single cells at a density of 3×10 4 cells/ml were deposited as drops on the lids of 90-mm Petri dishes to generate cellular aggregates. Lids with droplets attached were inverted over dishes filled with 10-ml PBS and incubated at 37°C in a 5% CO 2 incubator. NCI-H460 cancer cells were de-attached and MCTS were then obtained: (i) without CB1a treatment; (ii) with immediate CB1a treatment; (iii) post 30 min of CB1a treatment.
Cell images
Cell (NCI-H460 lung cancer cell and MRC-5 normal lung cell) damage induced by CB1a was observed by AFM (NanoWizard BioAFM, JPK, Germany) at a resolution of 512 × 512 pixels. A silicon-made AFM tip (NanoWorld, Switzerland) with a spring constant of 0.02 N/m was used for cell surface imaging measurement. After drug (CB1a or Dox) treatment, the medium was removed and the remaining sample washed by 1× PBS solution at pH 7.2. The desired cell was then fixed by 4% paraformaldehyde at room temperature for 10 min. The sample was rinsed again by 1X PBS buffer, water, and then air dried. The details of the set-up procedures for AFM to obtain cell morphology or mechanical property changes are shown in Appendix. Typical examples of "single cell" images (topology image and 3D configuration) by AFM tip are shown in Fig. 2 .
Young's modulus (E) measurement
A polystyrene bead (diameter~10 μm) was attached to the AFM tip by epoxy resin. The spring constant (0.04 N/m) of the bead-attached cantilever was calibrated in the cell culture medium by force modulation mode. All experiments were done within 30 min to insure living cells. Young's modulus, E, on the cell was determined by fitting a simplified parabolic geometric equation [52] :
where F is an applied external force, R is radius of tip, δ is the indentation depth of sample, which can be calculated by δ=h−d, where h is an indented piezo height and d is distance of cantilever's deflection. ν is Poisson's ratio (0.5 was used for soft biological sample). E is Young's modulus obtained after fitting with F vs. δ curve. An illustration of obtaining E on a single cancer cell after treatment with CB1a is shown in Fig. 3 (fitting curves are shown in bold). In these examples, Es were 760 pa and 119 pa for tip interaction time with the cell surface at 5 min and 19 min, respectively. Detailed results are given in the "Results" section below.
Results
Anti-cancer activity assays and multi-cellular tumor spheroids
Cytotoxicity assays of agents including CB, CB1a and Dox were done on lung cancer and normal lung cells. IC 50 s of these compounds are shown in Table 1 . As compared with CB, CB1a has lower IC 50 s on lung cancer cells (25.0 ± 1.6 μM for NCI-H460 and IC 50 = 22.7 ± 1.2 μM for NCI-H520) and equally higher IC 50 on normal lung cells (IC 50 > 100 μM for MRC-5). This implies that CB1a is outstandingly cytotoxic to lung cancer cells while not being seriously harmful to normal lung cells. For Dox, although it has lower IC 50 s on both lung cancer cell lines (18.4 ± 0.8 μM and 18.0 ± 1.0 μM for NCI-H460 and NCI-H520, respectively), the IC 50 on normal lung cells is even lower (only 16.6 ± 1.4 μM for MRC-5). In other words, Dox is more toxic to normal lung cells than abnormal cells with the potential for causing serious side-effects in cancer patients. Compared with Dox, CB1a seems to have much higher selectivity for lung cancer cells over normal lung cells.
In addition to in vitro toxicity testing of CB1a on cancer and normal cells above, further efficacy investigation of this peptide on cancer cell-aggregated tumor-like growths was identified by ex vivo MCTS modeling. In this case, NCI-H460 cancer cells were de-attached and MCTS were then obtained: (i) without CB1a treatment; (ii) with immediate CB1a treatment; (iii) post 30 min of CB1a treatment. Fig. 4A to C shows the respective results of the three different tumor growth scenarios. In Fig. 4A , a complete solid tumor-like growth formed when NCI-H460 cancer cells were added into a test tube. Fig. 4B shows a degraded tumor if CB1a peptide was added simultaneously to the test tube along with the cancer cells. Fig. 4C shows that only small spots formed in the test tube if CB1a peptide was added 30 min in advance of cell seeding. This result indicates that CB1a damages cancer cells and prevents cell-cell interaction/aggregation and consequently interrupts tumor-like growth.
AFM observations for single normal lung cell, MRC-5, treated with CB1a and Dox
(1) CB1a effect: AFM 3D images of single normal lung cell, MRC-5, under CB1a (25 μM) treatment at time 0, 0.5, 2, 8, 16 and 24 h are shown in Fig. 5A to F, respectively. For different incubation times, the cell nucleus (raised area in white) can be seen in each figure. This is consistent with no significant morphological change, indicating MRC-5 remained healthy for the times of the experiment; i.e., CB1a did not cause obvious injury to a normal lung cell during the 24 h test period. (2) Dox effect: Healthy MRC-5 cell was observed after dosing with 18 μM Dox at 2 h; 8 h; 16 h and 24 h and the results shown in Fig. 6A to D. By 8 h the cell had become flatter, by 16 h the cell nucleus had begun to breakdown and by 24 h the cell had completely collapsed. These results show that Dox is toxic to a normal lung cell within 8 h.
AFM observations for single lung cancer cell treated with CB1a
Cytotoxicity effects of CB1a on single human lung cancer cells, NCI-H460 and NCI-H520, were done by AFM observations. A cellular surface image of NCI-H460 without CB1a treatment is shown in Fig. 7A . The cell shape is smooth and round (diameter~35 μm) and it has a distinctive contour marking the nucleus. A similar observation for NCI-H520 without treatment with CB1a was obtained (see Fig. 7D ). Treatments with CB1a at different concentrations of 25 and 50 μM were done on two cell lines for 30 min. Results show that these single cells became sunken and appeared to have irregular shapes or ragged cellular configurations (see Fig. 7B and C for NCI-H460 and Fig. 7E and F for NCI-H520). These results indicate CB1a is highly toxic to cancer cells within 30 min.
Single cell surface damage determined by Young's modulus (E)
The physical changes in the properties of cell surface induced by CB1a are given by real-time measurement of E for a CB1a-treated single cell. Plots of normalized Young's modulus E vs. time are shown in Fig. 8 . Without CB1a treatment, E of NCI-H460 cell remained at about 1.0 (Fig. 8A ) within 25 min. After the addition of 12.5 μM CB1a, the level of E gradually declined to about 0.62 by 30 min (Fig. 8B) . These results indicate CB1a's effects on cell surface. However, the shape of the line is still similar to that of Fig. 8A; i.e., almost flat. The shape of the E line vs. time changes when the concentration of CB1a's increases to 25 μM. This result is similar to that of IC 50 (see Fig. 1 ). E drops in a reverse parabolic contour to about only 35% within 10 min. To give the expression of E physical meaning, a new term IT 50 is defined in this work. It indicates interaction time (IT) whereby E is reduced by 50%. Accordingly, IT 50 s of CB1a on NCI-H460 were 7.0 min at 25 μM (see Fig. 8C ) and 4.8 min at 50 μM (see Fig. 8D ). Furthermore, E for CB1a-treated MRC-5 normal lung cell was also investigated. Plots of normalized E vs. time for CB1a at 5 and 25 μM are shown in 4 and B, respectively. Both Es were more or less constant (at around 1.0) and IT 50 s were infinite. These results indicate no changes to the physical condition of the normal lung cell under treatment with CB1a at 25 μM within 30 min.
Discussion
Therapeutic drugs work via chemical or physical pathways in the treatment of cancer cells. A physical attack on a cancer cell is one where cellular membranes are compromised leading to cell death.
Understanding the mechanism of cellular death is essential for the development of peptides as anticancer drugs. This paper investigates a customized peptide from the CB group, CB1a, to see how cell damage occurs in a single cell by AFM microscopic observations and test the efficacy and selectivity of CB1a against lung cancer cells. Before the single cell measurements, general investigations of IC 50 for CB1a on lung cancer and normal lung cells via MTT assay were performed. We used the current clinically available drug, Dox, as a reference compound. Based on the results of MTT assay, CB1a has high selectivity for lung cancer cells over normal cells. Its selectivity was much better than that of Dox. The Selectivity Index (SI) of CB1a (SI is a ratio of IC 50 on normal lung cells to that of lung cancer cells) is larger than 15 on average, while, SI of Dox is mostly less than 1 (data not shown). Further evidence of CB1a's efficacy on lung cancer cells was obtained using MCTS modeling. Results indicated that CB1a had the ability to prevent lung cancer cells (NCI-H460) from forming tumor-like growths in test tubes. MCTS modeling gives guidance on the aggregation of cancer cells under gravity whereby cell-cell interactions are the main force allowing for cell aggregations to occur in solution. Under these circumstances, if cancer cell surfaces are not viable (compromised by physical attack from CB1a) they cannot interact with healthy cancer cell surfaces and aggregation is partially inhibited or cannot occur. This is shown in Fig. 4B and C for addition of CB1a at the time of seeding with cancer cells and 30 min prior to seeding, respectively. The example of adding CB1a to solution 30 min prior to seeding with cancer cells may tell us something of how this mechanism works. If cancer cell surfaces are more efficiently compromised by CB1a in solution then they have no time to interact with healthy cancer cells and aggregation is prevented (Fig. 4C) . Dose dependence of CB1a on MCTS is further evidence of this (data not shown). These results could provide a future model for animal tests with peptide injections done in advance of the introduction of cancer cells. From a clinical point of view, if tolerated and deliverable, CB1a peptide could be used in early stage treatments or post surgery treatments when cancer cells are not so abundant. Furthermore, CB1a shows promise because of its high selectivity for cancer cells and low damage to normal lung cells (MRC-5, under CB1a (25 μM) at time = 24 h showed no obvious damage to cells, see Fig. 5F ). CB1a's unique toxicity characteristics for normal tissue vs. cancerous tissue may be more favorable than those clinical drugs used for curing lung cancer.
The evidence of CB1a's efficacy in killing cancer cells in vitro made investigating the mechanism at a cellular level worthwhile. Current cancer drug Dox was again used as a reference compound. Morphological change of the cell surface during treatment with both drugs was investigated in real time using AFM. The study shows very different results for CB1a and Dox on normal lung cell, MRC-5. For Dox dosage of 18 μM, the normal cell's nucleus collapsed after an incubation time of 8 h. However, there was no evidence of damage to either the nucleus or cell as a whole under CB1a at 25 μM even after 24 h (see Fig. 5 ). Meanwhile, cancer cells NCI-H460 and NCI-H520 treated with CB1a at 25 μM showed considerable cellular breakdown after only 30 min (see Fig. 7 ). Clearly, CB1a is highly toxic to cancer cells, but has low toxicity toward normal cells. Consequently, we think CB1a has many favorable characteristics as a chemotherapeutic drug.
Further evidence of the mechanism by which CB1a kills cancer cells is provided by studying the changes in a cell's physical properties. Healthy cells have elastic properties. Under pressure (for example, from the external force applied by an AFM tip) a cell's shape becomes deformed but once the force is removed it will spring back to its original shape. However, if the cell surface is damaged (or membrane broken) by a drug like CB1a peptide, the cell loses its elasticity and this can be observed as a function of time. This work is the first of its kind to show cell degradation caused by CB1a and its direct relationship with elasticity change (or Young's modulus, E, change). The results confirmed that E reduced as a function of time when CB1a peptide was added to cancer cells. However, when CB1a was added to normal cells, E was almost a constant with time. This paper proposes that a new measure of drug efficacy IT 50 be used in standard operating procedures (SOP) for future drug verification. IT 50 is the interaction time between drug and target cell whereby E is reduced by 50%. Compared to the current standard IC 50 , IT 50 can be used as a measure at the single cell level over time whereas IC 50 looks at bulk solutions. For example, for CB1a-treated NCI-H460 cancer cell, a reversed parabolic curve of E vs. time was obtained at 25 μM (see Fig. 8C ) with IT 50 of about 7.0 min. The IC 50 of CB1a was 25 μM. Both IT 50 (7.0 min) and IC 50 (25 μM) can therefore be considered as cross verification for drug efficacy in in vitro investigations.
Dox uses a chemical pathway to kill cells through interaction with DNA by intercalation and inhibition of macromolecular biosynthesis [53, 54] . The time needed to complete this inhibition action in cells leading cell to death for Dox may be longer (several hours) than CB1a requires to do physical damage to cancer cells (only about 20 min). The quickness with which CB1a kills cells may be explained by our previous results that CB1a peptide first binds with cancer cell surfaces through heparin-like binding and is then forced into the lipid membrane by hydrophilic and hydrophobic interactions with lipid heads and tails, respectively [39] .
Conclusions
A customized anticancer peptide, CB1a, is shown to have high toxicity against lung cancer cells NCI-H460 and NCI-H520. It is also shown to be highly selective for these cells over normal lung cells, MRC-5. These two qualities suggest CB1a would make a good candidate for drug development. Additionally, the paper presents a new method for measuring drug efficacy IT 50 -interaction time between drug and target cell whereby Young's Modulus E is reduced by 50%. For these experiments, CB1a has been shown to be potent against lung cancer cells with an IC 50 of 25 μM and IT 50 of 7.0 min. The cell death time was very quick and could be observed in real-time by AFM measurement. If compounds kill cells by a physical attach mechanism, IT 50 may be an efficient method for verifying drug efficacy.
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Appendix A AFM set-up for cell observation by microscope was shown below diagram. Sample showing cell surface and inside of cell (in light and dark reds, respectively) viewed by light microscope. AFM tip was properly adjusted to touch the cell. Upon scanning the cell by tip, the interaction force between the tip and cell surface causes a deflection. This deflection can be identified by a shift in the laser beam which is detectable by a quadrant photodiode. During data processing, all electric signals are transformed into either height (μm) or force (N) and both a topographic image and force relationship curve could be obtained (see right-side figures). 
